Enriching knowledge and enhancing care through health data

From Electronic Health Records to Electronic Data Capture systems

The goal of EHR2EDC  is to improve and commercialise a clinical research technology platform (InSite) enabling a trustworthy re-use of Electronic Health Records (EHR) data to improve global research and accelerate access to treatment innovations. It seeks to improve connections between EHR and Electronic Data Capture systems, to enhance the value of the InSite platform.


This project has three areas of activity:

  1. A new InSite platform service, to enable direct data capture from EHRs to Electronic Case Report Form.
  2. An education and training programme for hospitals staff, to increase data quality.
  3. An increase in the number of connected hospitals, to support patient recruitment in Europe.

This project leverages the EHR4CR project, a pre-competitive industry collaboration in which eight global companies join forces in scaling up adoption, and creating more added-value from the InSite clinical research technology platform. Through that project, backed by the EC's Innovative Medicine Initiative, hospital EHR systems were connected with the current InSite version, which offers two services to optimise clinical protocols and support patient recruitment.

This current project will primarily fund the technological development, of a third added-value service, to enable clinical trial investigators within each hospital, to transfer EHR data into their clinical trial Electronic Data Capture system, avoiding significant duplicative effort and time. This increases the overall attractiveness of the solution to the research community.

EHR2EDC will develop an educational programme, to support all networked hospitals with enhancing their EHR system use and data quality, so they can increase the value of their data for their own use, achieve quality improvement and facilitate research.

During the project, the hospital engagement programme will target the growth of the network to reach more than 120 organisations by the end of 2019, expanding outside of Europe.

Target Group

Audience: Pharma industry, academia, governmental institutions.

Market: Global clinical trial market, both institutional and industrial – totalling about 5 000 trials in Europe and 22 000 clinical trials annually worldwide. This market, was estimated to be worth $14.2 billion in 2016, and is expected to be worth $22 billion by 2021.

This consortium has published peer reviewed modelling of the incremental adoption of this solution, with conservative numbers still confirming economic viability.



Assistance Publique - Hôpitaux de Paris
Astra Zeneca
INSERM - French National Institute of Health and Medical Research
Janssen-Cilag GmbH
UCB Biosciences GmbH
Published on: 01 April 2018